Access to Rare Indications Act of 2020
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Sep 30, 2020)
Access to Rare Indications Act of 2020
This bill prohibits coverage exclusions or limitations under the Medicare prescription drug benefit, Medicaid, or private health insurance of certain drugs that are used to treat rare diseases or conditions (i.e., diseases or conditions that affect 200,000 or fewer individuals and that are supported by the National Institutes of Health Rare Diseases Clinical Research Network).
What just happenedSep 30, 2020
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Who’s behind it
- Introduced in HouseSep 30, 2020
- Sep 30, 2020IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Ways and Means Committee - Sep 30, 2020IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Sep 30, 2020IntroReferralIntro-H
Introduced in House
- Sep 30, 2020IntroReferral1000
Introduced in House